Nuclear reactor developer X-Energy prices upsized $1 billion IPO advised by Latham & Watkins and Skadden
X-Energy, a developer of small modular nuclear reactors (SMRs) and advanced nuclear fuel technology, began trading on Friday after pricing an upsized initial public offering (IPO) at $1 billion — making it one of the largest US energy-sector listings of 2026. Latham & Watkins advised the issuer while Skadden acted on the transaction, though the specific roles of each firm were not separately disclosed in the available sources. The IPO is a landmark moment for the SMR sector. SMRs — compact, factory-built nuclear reactors with capacity typically below 300 MW — have attracted significant government and private backing as a baseload-power solution compatible with net-zero energy grids. X-Energy's reactor design, the Xe-100, uses a high-temperature gas-cooled pebble-bed architecture and has been supported by the US Department of Energy's Advanced Reactor Demonstration Programme. The timing is deliberate: the Iran conflict has driven global LNG prices sharply higher and exposed the fragility of gas-dependent grids across Europe and Asia, reigniting political and investor appetite for nuclear as a firm-power alternative that is not exposed to fossil fuel supply chains. A $1 billion listing, upsized from its original target, suggests institutional demand was strong. The transaction also adds momentum to an otherwise stop-start IPO market in 2026, offering a data point that thematic energy listings can clear the market even in an uncertain macro environment.
Why this matters
X-Energy's $1 billion listing confirms that SMR developers can access public capital markets at scale — a signal that will pull forward IPO planning at competing nuclear developers and unlock follow-on equity raising once lock-up periods expire. The transaction is primarily a US capital markets event, but the SMR regulatory and licensing framework question is directly live in the UK, where Great British Nuclear is running its own SMR competition, and Rolls-Royce's SMR programme is seeking investment. Any UK SMR developer eyeing a London listing will study X-Energy's prospectus structure and valuation multiples closely. From a practice area perspective, the deal activates equity capital markets work (prospectus drafting, SEC registration), energy regulatory advice (Nuclear Regulatory Commission licensing risk disclosure), and IP due diligence on proprietary reactor designs.
On the Ground
A trainee on the issuer-side team would assist with prospectus proofreading and verification note preparation — checking every factual claim in the prospectus against source documents including government grant letters, reactor licensing submissions, and partnership agreements. They would also coordinate comfort letter requests from the company's auditors and prepare PDMR (person discharging managerial responsibilities) notification letters for directors dealing in shares around the IPO.
Interview prep
Soundbite
A $1 billion SMR IPO proves public equity markets will price nuclear power as a credible energy-transition asset class.
Question you might get
“What are the most legally complex disclosures an SMR developer would need to include in a UK listing prospectus, and how does nuclear regulatory licensing risk affect the prospectus liability framework?”
Full answer
X-Energy has priced a $1 billion upsized IPO, becoming one of the most significant nuclear energy listings in the US capital markets in recent years. The commercial significance for law firms is direct: a successful listing at this scale will pull forward IPO timelines at other SMR developers globally, generating prospectus drafting, regulatory disclosure, and underwriter advisory work. The 'why now' trigger is structural — the Iran conflict has made gas-dependent energy supply appear permanently fragile, rehabilitating nuclear as politically and commercially viable across Western markets. In the UK specifically, the Great British Nuclear SMR programme and Rolls-Royce's reactor plans mean London advisers need to understand how a comparable listing would need to be adapted for the FCA's listing rules and the ONR's (Office for Nuclear Regulation's) regulatory risk disclosure framework. I think this IPO sets a pricing anchor that UK SMR developers will reference when approaching the London Stock Exchange.
My notes
saved